114 related articles for article (PubMed ID: 26704167)
1. [Anti-EGFR monoclonal antibodies in recurrent and/or metastatic head and neck squamous cell carcinoma: a meta-analysis].
Song Q; Li X; Li B; Di B; Xiao S
Zhonghua Yi Xue Za Zhi; 2015 Jun; 95(22):1779-83. PubMed ID: 26704167
[TBL] [Abstract][Full Text] [Related]
2. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
3. [Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: a Meta-analysis].
Song Q; Li X; Li B; Di B; Xiao S
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 May; 29(9):815-21. PubMed ID: 26281058
[TBL] [Abstract][Full Text] [Related]
4. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.
Zhang S; Chen J; Jiang H; Ma H; Yang B
Eur J Clin Pharmacol; 2012 May; 68(5):561-9. PubMed ID: 22231637
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y
Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma.
Xin Y; Yan Q; Yang C; Jiang F; Guo W; Huang Q; Jiang G; Zhang L
Medicine (Baltimore); 2018 Dec; 97(51):e13717. PubMed ID: 30572506
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
Han X; Zhang H; Sun K; Li J; Wu W; Liu K; Yu Z
Front Immunol; 2023; 14():1302840. PubMed ID: 38299153
[TBL] [Abstract][Full Text] [Related]
8. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
9. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
10. Combination immunochemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Xu Q; Huang S; Yang K
BMJ Open; 2023 Jun; 13(6):e069047. PubMed ID: 37311638
[TBL] [Abstract][Full Text] [Related]
11. The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: A systematic review and meta-analysis.
Nie D; Wang X; Sun M; Feng Z; Pei F; Liu W; Wang Z; Han F
Radiother Oncol; 2021 May; 158():13-20. PubMed ID: 33587969
[TBL] [Abstract][Full Text] [Related]
12. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
13. Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis.
Petrelli F; Barni S
Head Neck; 2012 Nov; 34(11):1657-64. PubMed ID: 21953841
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.
Lau A; Yang WF; Li KY; Su YX
Crit Rev Oncol Hematol; 2020 Sep; 153():102984. PubMed ID: 32569853
[TBL] [Abstract][Full Text] [Related]
15. p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis.
Su Y; Cui J; Xu D; Wang M; Xu T; Tian H; Han F
Crit Rev Oncol Hematol; 2018 Apr; 124():11-20. PubMed ID: 29548481
[TBL] [Abstract][Full Text] [Related]
16. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.
Machiels JP; Specenier P; Krauß J; Dietz A; Kaminsky MC; Lalami Y; Henke M; Keilholz U; Knecht R; Skartved NJ; Horak ID; Pamperin P; Braun S; Gauler TC
Cancer Chemother Pharmacol; 2015 Jul; 76(1):13-20. PubMed ID: 25952795
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
Siano M; Molinari F; Martin V; Mach N; Früh M; Freguia S; Corradino I; Ghielmini M; Frattini M; Espeli V
Oncologist; 2017 Jul; 22(7):782-e70. PubMed ID: 28592616
[TBL] [Abstract][Full Text] [Related]
18. Current Role of Dacomitinib in Head and Neck Cancer.
Elicin O; Ozsahin M
Expert Opin Investig Drugs; 2016 Jun; 25(6):735-42. PubMed ID: 27070370
[TBL] [Abstract][Full Text] [Related]
19. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Sacco AG; Cohen EE
J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]